Cargando…
A first‐in‐human pharmacodynamic and pharmacokinetic study of a fully human anti‐glucagon receptor monoclonal antibody in normal healthy volunteers
AIMS: Glucagon receptor (GCGR) blockers are being investigated as potential therapeutics for type 1 and type 2 diabetes. Here we report the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of REGN1193, a fully human glucagon receptor blocking monoclonal antibody from a first‐in‐...
Autores principales: | Kostic, Ana, King, Thomas Alexander, Yang, Feng, Chan, Kuo‐Chen, Yancopoulos, George D., Gromada, Jesper, Harp, Joyce B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5813272/ https://www.ncbi.nlm.nih.gov/pubmed/28755409 http://dx.doi.org/10.1111/dom.13075 |
Ejemplares similares
-
Glucagon orchestrates stress‐induced hyperglycaemia
por: Harp, J. B., et al.
Publicado: (2016) -
Study of GABA in Healthy Volunteers: Pharmacokinetics and Pharmacodynamics
por: Li, Junfeng, et al.
Publicado: (2015) -
Glucagon contributes to liver zonation
por: Cheng, Xiping, et al.
Publicado: (2018) -
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the CGRP Binding Monoclonal Antibody LY2951742 (Galcanezumab) in Healthy Volunteers
por: Monteith, David, et al.
Publicado: (2017) -
The Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel in Healthy Japanese Volunteers
por: Umemura, Kazuo, et al.
Publicado: (2016)